CAESAREA, Israel - IceCure Medical Ltd. (NASDAQ:ICCM), known for its ProSense® cryoablation technology, has released new data from an independent breast cancer study showing a median tumor size reduction of 100% at both 6 and 12 months post-treatment.
The study, led by Dr. Federica di Naro at Azienda Ospedaliero-Universitaria Careggi in Florence, Italy, involved 39 women between the ages of 60 and 92 who were considered inoperable due to age and comorbidities or had refused surgery.
The ProSense® System, which is approved in Italy for various indications including breast cancer, was utilized for ultrasound-guided cryoablation of biopsy-proven malignant lesions.
The treatment's efficacy was assessed using ultrasound to measure tumor size reduction at intervals of 1, 3, 6, and 12 months after the procedure. At the 12-month mark, the absence of residual tumor cells was confirmed through core needle biopsy and contrast-enhanced mammography.
IceCure's CEO, Eyal Shamir, expressed satisfaction with the study's results, emphasizing the potential benefits for patients deemed inoperable. The company is striving to make ProSense® more accessible and affordable in numerous countries.
The ProSense® Cryoablation System offers a minimally invasive alternative to surgical tumor removal, utilizing liquid nitrogen to destroy both benign and malignant tumors. It is designed for ease of use and transport, enabling quick office-based procedures for breast tumors.
The information presented in this article is based on a press release statement from IceCure Medical.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.